Histopathologic analysis of angiogenic factors in localized renal cell carcinoma: The influence of neoadjuvant treatment

被引:11
|
作者
Kawata, N [1 ]
Yagasaki, H [1 ]
Yuge, H [1 ]
Nakanoya, Y [1 ]
Fujimura, K [1 ]
Sugimoto, S [1 ]
Hirakata, H [1 ]
Takimoto, Y [1 ]
机构
[1] Nihon Univ, Sch Med, Dept Urol, Surugadai Nihon Univ Hosp,Chiyoda Ku, Tokyo 1018309, Japan
关键词
angiogenesis; Factor VIII-related antigen; localized renal cell carcinoma; postoperative recurrence; thymidine phosphorylase;
D O I
10.1046/j.1442-2042.2001.00299.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: This study was conducted in order to clarify whether histopathologic analysis of factor thymidine phosphorylase (TP) and Factor VIII could be a useful predictor of postoperative recurrence in localized renal cell carcinoma. Therefore, the relationship between tumor infiltrated lymphocytes (TIL) and both TP and Factor VIII was studied. Method: Of the 71 patients who underwent surgery, 54 patients had no neoadjuvant therapy (group 1), 10 patients were preoperatively administered IFN-gamma (group 2), and the remaining seven patients preoperatively received IFN-gamma and transarterial embolization (group 3). Both TP and Factor VIII immunostaining were performed on formalin-fixed, paraffin-embedded archival tissue from 71 renal cell carcinoma specimens, while TIL immunostaining was performed on frozen sections. Positive immunostaining was quantitatively scored by a computer-assisted digital image analysis. For TIL, positive results were semiquantitatively scored. Results: A significant difference in the recurrence-free rate was recognized for Groups 1, 2 and 3 (P < 0.05). Therefore, the median TP-positive rate (PR), VIII-PR, number of microvessels and positive mean vascular area levels were investigated, between the recurrence cases (n = 6) and the recurrence-free cases (n = 11). Only the TP-PR levels showed a significant difference among them (P = 0.044). In regards to the neoadjuvant cases, a significant correlation was observed between both VIII-PR and CD4 (r = 0.815) as well as between VIII-PR and CD11b (r = 0.756). Conclusion: There was no clear evidence that the neoadjuvant treatment would increase the recurrence-free survival in patients with localized renal cell carcinoma. TP-PR might be a predictor of postoperative recurrence in patients with localized renal cell carcinoma.
引用
收藏
页码:275 / 281
页数:7
相关论文
共 50 条
  • [41] Prognostic factors and treatment decisions in renal cell carcinoma
    Ljungberg, B
    RENAL, BLADDER, PROSTATE AND TESTICULAR CANCER: AN UPDATE, 2001, : 37 - 46
  • [42] Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma
    Wood, Christopher G.
    Ferguson, James E.
    Parker, Joel S.
    Moore, Dominic T.
    Whisenant, Jennifer G.
    Maygarden, Susan J.
    Wallen, Eric M.
    Kim, William Y.
    Milowsky, Mathew, I
    Beckermann, Kathryn E.
    Davis, Nancy B.
    Haake, Scott M.
    Karam, Jose A.
    Bortone, Dante S.
    Vincent, Benjamin G.
    Powles, Thomas
    Rathmell, W. Kimryn
    JCI INSIGHT, 2020, 5 (22)
  • [43] Histopathologic and Immunohistochemistry Findings in Feline Renal Cell Carcinoma
    Matsumoto, Isao
    Chambers, James K.
    Nibe, Kazumi
    Kinoshita, Ryohei
    Nishimura, Ryohei
    Nakayama, Hiroyuki
    Uchida, Kazuyuki
    VETERINARY PATHOLOGY, 2018, 55 (05) : 663 - 672
  • [44] Histopathologic effects of neoadjuvant therapies for advanced squamous cell carcinoma of the esophagus: multivariate analysis of predictive factors and p53 overexpression
    Kajiyama, Y
    Hattori, K
    Tomita, N
    Amano, T
    Iwanuma, Y
    Narumi, K
    Udagawa, H
    Tsurumaru, M
    DISEASES OF THE ESOPHAGUS, 2002, 15 (01) : 61 - 66
  • [45] NEOADJUVANT ANTI-ANGIOGENIC TREATMENT OF RENAL CELL CANCER AND ITS EFFECT ON TUMOR BLOOD VESSELS
    Tilki, Derya
    Haseke, Nicolas
    Reich, Oliver
    Seitz, Michael
    Stief, Christian
    Staehler, Michael
    Erguen, Suleyman
    JOURNAL OF UROLOGY, 2010, 183 (04): : E33 - E33
  • [46] Multivariate analysis of the parameters affecting the choice of surgical treatment for patients with localized renal cell carcinoma (RCC)
    Pikul, Maksym
    Voylenko, Oleg
    Stakhovskyi, Oleksandr
    Semko, Sofiya
    Vitruk, Iurii
    Kononenko, Oleksii
    Hrechko, Bohdan
    Tymoshenko, Andrii
    Paffenholz, Pia
    Pfister, David
    Bach, Christian
    Rieger, Constantin
    Stakhovsky, Eduard
    Heidenreich, Axel
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 (12)
  • [47] Neoadjuvant treatment in advanced renal cell carcinoma: current situation and future perspectives
    Timsit, Marc-Olivier
    Albiges, Laurence
    Mejean, Arnaud
    Escudier, Bernard
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (12) : 1559 - 1569
  • [48] Survival analysis for localized low-differentiated renal cell carcinoma
    Golubinski, A.
    Gliniewicz, B.
    Slojewski, M.
    Sikorski, A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (08) : 591 - 591
  • [49] Neoadjuvant targeted therapy in renal cell carcinoma
    Iacovelli, Roberto
    Raimondi, Cristina
    Palazzo, Antonella
    Cortesi, Enrico
    Procopio, Giuseppe
    NATURE REVIEWS UROLOGY, 2010, 7 (07) : 1 - 1
  • [50] MR texture analysis in the differentiation of renal oncocytoma with localized renal cell carcinoma subtypes
    Wang, Yichen
    Zhang, Xinxin
    Wang, Sicong
    Chen, Yan
    BRITISH JOURNAL OF RADIOLOGY, 2023, 96 (1148):